Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs Tramadol
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Moderate to moderately severe pain (FDA-approved),Chronic pain (off-label),Restless legs syndrome (off-label),Premature ejaculation (off-label),Osteoarthritis pain (off-label)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Hepatic via CYP2D6 and CYP3A4 to active metabolite O-desmethyltramadol (M1) and other inactive metabolites; undergoes conjugation.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
38-45%, primarily bound to albumin.
Approximately 20% bound to plasma proteins (primarily albumin).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Approximately 2.6-3.0 L/kg (306-350 L for a 70 kg adult), indicating extensive tissue distribution.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: approximately 70-75% (high first-pass metabolism). Rectal: similar to oral. Intramuscular: 100% (relative to IV).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Cr Cl 30-59 m L/min: extend dosing interval to every 12 hours. Cr Cl <30 m L/min: extend interval to every 12 hours and consider max dose 200 mg/day. Hemodialysis: administer dose after dialysis, with same interval adjustments.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A (mild): 50 mg every 12 hours. Child-Pugh Class B (moderate): 50 mg every 12 hours. Child-Pugh Class C (severe): not recommended.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Age ≥16 years: same as adult dosing. Age 12-15 years: 50-100 mg orally every 4-6 hours; max 400 mg/day. For children <12 years: not recommended.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Initiate at 25 mg orally every 6 hours as needed; titrate cautiously to 50 mg every 6 hours; max 300 mg/day. Consider creatinine clearance for dose adjustments.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interactions with drugs affecting CYP450 isoenzymes; risk of serotonin syndrome; risk of seizures; risk of suicide in patients with depression.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Respiratory depression; seizures; serotonin syndrome; suicide risk; adrenal insufficiency; severe hypotension; use in renal/hepatic impairment; anaphylaxis; use with MAOIs; use in pregnancy (neonatal withdrawal); use in breastfeeding.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity; concomitant use of MAOIs or within 14 days; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; use in children <12 years for post-tonsillectomy/adenoidectomy pain.
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
No significant food interactions. Grapefruit juice does not substantially affect tramadol metabolism. Avoid alcohol entirely due to additive CNS depression and increased risk of hepatotoxicity. St. John's Wort may reduce tramadol efficacy by inducing CYP3A4 and CYP2D6. High-fat meals may delay absorption but do not significantly affect overall exposure; take extended-release tablets consistently with or without food.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trimesters: Risk of neonatal respiratory depression, withdrawal syndrome, and reduced fetal growth with chronic use. Avoid or use lowest effective dose.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Tramadol is excreted into breast milk; relative infant dose estimated at 0.1-3.1% of maternal weight-adjusted dose. M/P ratio approximately 1.3. Monitor infant for drowsiness, feeding difficulties, and constipation. Avoid in mothers with CYP2D6 ultra-rapid metabolism due to increased opioid exposure.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Increased clearance and volume of distribution in pregnancy may reduce serum levels; consider dose increase by 20-30% if inadequate analgesia. Avoid in third trimester near delivery due to risk of neonatal respiratory depression. Use lowest effective dose for shortest duration.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active metabolite M1 for analgesic effect. Poor metabolizers (7-10% of population) may experience reduced efficacy. Caution with serotonergic drugs due to risk of serotonin syndrome. Seizure risk increased in patients with epilepsy, history of seizures, or concomitant use of SSRIs, SNRIs, tricyclic antidepressants, or other drugs that lower seizure threshold. Dose adjustment needed in renal impairment (Cr Cl <30 m L/min: extended interval or avoid) and hepatic cirrhosis (reduce dose or extend interval). Avoid use in patients with severe hepatic impairment. Not recommended for children <12 years, or <18 years for tonsillectomy/adenoidectomy. Maximum single dose: 100 mg; maximum daily dose: 400 mg (300 mg in patients >75 years). Onset of action: 30-60 minutes; peak effect: 2-3 hours; duration: 4-6 hours.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, and overdose.,Tramadol may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not stop abruptly; withdrawal symptoms (anxiety, sweating, insomnia, pain) may occur. Taper under medical supervision.,Report symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, diarrhea) immediately.,Seek emergency help if you experience slow/shallow breathing, severe drowsiness, or difficulty waking up.,Dispose of unused tramadol properly via drug take-back programs to prevent accidental ingestion or misuse.,Inform your doctor of all medications you take, especially antidepressants, antipsychotics, and pain relievers.,Pregnancy: avoid during labor; prolonged use may cause neonatal withdrawal syndrome. Breastfeeding: not recommended.,Grapefruit juice has not been shown to interact significantly, but avoid excessive intake.
No interactions on record
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs Tramadol, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. Tramadol is a Opioid Agonist that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and Tramadol depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of Tramadol is: 50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and Tramadol in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. Tramadol is classified as Category D/X. First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.